Combination of cd37 antibodies with chlorambucil
AssigneeBoehringer Ingelheim International GmbH
InventorsKarl-Heinz HEIDER, Petra BLUM
Life of this patent
Estimating the term…
Abstract
The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and chlorambucil. The combination of CD37 antibodies and chlorambucilis shown to have a synergistic effect. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.
Claims20
A method of using a CD37 antibody in combination with chlorambucil for treating patient suffering from a CD37-positive malignancy, wherein the CD37 antibody comprises:
- a variable heavy chain comprising CDRs have the SEQ ID NOs:
- 15, 16 or 21, and 17, and
- a variable light chain comprising CDRs having the SEQ ID NOs:
- 18, 19 and 20.
A method of reducing CD37-positive cells comprising:
- a) Exposing CD37-positive cells to a CD37 antibody and
- b) Exposing CD37-positive cells to chlorambucil,
- wherein said CD37 antibody of step a) comprises:
- i) a variable heavy chain comprising CDRs have the SEQ ID NOs:
- 15, 16 or 21, and 17, and
- ii) a variable light chain comprising CDRs having the SEQ ID NOs:
- 18, 19 and 20.
20-34. (canceled)
Dependencies are inferred from the claim text.